Medically Reviewed By
— Written By
— Updated on September 16, 2026
The fast facts
On this page
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.
When asked where MUSE cell research is heading, most sources respond with a list of conditions. A list of conditions is not a map of a field; it says nothing about which areas carry a real weight of published work, which rest on a single paper, and which appear only in marketing.
This page surveys where the investigation is actually concentrated. It does not set out the intrinsic biology of the cells’ markers, classification, and differentiation behaviour, which sits outside its scope, and it does not restate what the published clinical studies found; that record, with phases, enrolments, and outcomes, is in our overview of MUSE cell clinical trials. What follows is the shape of the research landscape and an honest account of its limits.
Reading a field at this stage
Two habits make the difference between reading this literature well and misinterpreting it.
The first is distinguishing model systems from clinical evidence. Almost everything below is animal work: mice, rats, mini-pigs. That is the appropriate stage for most of these questions, and it is not a weaker version of a human finding. It is a different category of finding, and describing it accurately means saying which species, which model, and what was measured.
The second is noticing what a study was designed to do. Preclinical application research asks whether a defined intervention changes a defined outcome in a controlled model. It is not the same thing as tracking outcomes among people who obtained a product outside any controlled study, a category that has begun appearing in registry listings and does not belong in a survey of research applications. Where such records exist, they describe self-directed acquisition rather than investigation, and folding them into a discussion of “potential” blurs precisely the distinction a physician needs to keep sharp.
Neurological models: the densest area
Central nervous system models carry the most published work and the most recent.
Two studies from the same group illustrate both the direction and the pace. Yamamoto and colleagues, in Scientific Reports in 2025, examined intranasal delivery in a murine permanent middle cerebral artery occlusion model, administering 6.0 × 10⁴ MUSE cells seven days after the event against low- and high-dose mesenchymal stromal cell comparators, with motor function assessed by accelerated rotarod across 84 days. The MUSE group showed continuous improvement in motor function with statistical significance against the other groups, while the high-dose mesenchymal group showed transient recovery only; engraftment in the peri-infarct area was substantially higher, with 63.6% of engrafted cells expressing neuronal markers.
Shiraishi and colleagues followed up in Scientific Reports in 2026 with a traumatic brain injury model in forty mice, injecting 6.0 × 10⁴ cells intravenously seven days after injury against low- and high-dose mesenchymal comparators and a vehicle control. Recovery on rotarod and cylinder testing was significantly enhanced at 28 and 42 days, with roughly 60% of transplanted cells expressing neuronal markers and 20% expressing oligodendrocyte markers.
Both are forty-animal characterisation studies with functional and histological endpoints. Neither is evidence of clinical benefit, and both are cited here as indicators of where the work is concentrated.
Cardiac and vascular models
Cardiac work is the second substantial cluster, and it extends to large-animal models a step most areas in this field have not reached.
Yamada and colleagues, in PLOS ONE in 2022, used a mini-pig model of acute myocardial infarction induced by 30 minutes of coronary occlusion followed by two weeks of reperfusion, administering 10⁷ human MUSE cells intravenously at 24 hours against a saline control. Infarct size was reduced (10.5 ± 3.3% against 21.0 ± 2.0%), with improved ejection fraction and fractional shortening, smaller ventricular dimensions, enhanced vascularisation, and no arrhythmias detected on an implantable loop recorder.
Peripheral vascular models sit alongside it. Hori and colleagues, in Frontiers in Cardiovascular Medicine in 2022, reported recovered blood flow, increased microvascular density, and reduced fibrotic area in a mouse hindlimb ischaemia model following intravenous administration.
A distinct strand within cardiac research looks at endogenous MUSE cells rather than administered ones. Toyoda and colleagues, in Clinical and Translational Science in 2024, counted endogenous MUSE cells in biopsied myocardial tissue from seventeen patients with fulminant myocarditis against six controls, correlating counts with cardiac biomarkers and recovery. Nothing was administered to anyone in that study it is observational work on cells already present, and it is a legitimate part of the picture.
Hepatic and organ-preservation models
Liver work runs in two directions.
The first is fibrosis. Iseki and colleagues, in Cell Transplantation in 2017, used a carbon tetrachloride model of liver fibrosis in immunodeficient mice with intravenous administration at intervals, reporting reduced fibrotic area and differentiation of integrated cells into hepatocyte-like cells.
The second is organ preservation, which is a different research question and a less crowded one. Shono and colleagues published on protection of liver sinusoids following intravenous administration of human MUSE cells in a rat extra-small partial liver transplantation model in the American Journal of Transplantation in 2021. Naming it here rather than summarising its findings is deliberate: the citation is confirmed across multiple indexes, but the full text was not accessible for this survey, so no outcome figures are quoted from it.
Route of delivery is becoming its own question
Worth noting as a direction in its own right, because it cuts across every area above.
The bulk of published work uses intravenous administration, which relies on the cells reaching a target through the circulation. The mechanism behind that distribution is a separate subject and is not detailed here. The 2025 murine stroke study above used intranasal delivery instead. When a field begins comparing routes rather than only comparing doses, it is a signal that basic feasibility questions are considered settled enough to optimise around. [3–7]
The bulk of published work uses intravenous administration, which relies on the cells reaching a target through the circulation. The mechanism behind that distribution is a separate subject and is not detailed here. The 2025 murine stroke study above used intranasal delivery instead. When a field begins comparing routes rather than only comparing doses, it is a signal that basic feasibility questions are considered settled enough to optimise around. [3–7]
Where the literature is thin, and where it is absent
A survey that only lists strengths is a brochure.
Institutional concentration is the clearest limitation. Trace the author lists across the studies above and a single research lineage recurs. [1–7] That is normal for a field fifteen years from its founding paper, and it means the evidence base has less institutional and methodological diversity than a mature area would show a limitation of stage rather than a criticism of the work.
Model sizes are small. Forty animals is a characterisation study, not a powered comparison. Doses, timings and comparators differ between studies, so results are not directly comparable to one another.
And some areas that appear prominently in commercial material have no supporting published research at all. Where a condition appears in advertising but not in the literature, the absence is the finding.
What shapes the next phase
The material CellGenic supplies is for laboratory research use only and must not be administered to humans or animals in any form. The studies surveyed here were conducted by third parties with their own materials under their own determinations, and are described as published literature. Manufacturing is cGMP, processing is performed in an ISO 7 cleanroom, and a certificate of analysis is issued for every batch, identified by batch number.
Two structural facts, rather than predictions.
The clinical programme that generated the published human studies is closed its developer discontinued the product in February 2023, a matter covered in our clinical trials overview. Preclinical characterisation, as the 2025 and 2026 studies above show, has continued without it.
The second is process research: work examining how culture conditions affect the proportion of MUSE cells within a mesenchymal population a proportion whose measurement and denominators are set out in MUSE cells vs. mesenchymal stem cells. That question sits upstream of every application area, because it determines what a given preparation contains.
What a survey establishes, and what it does not
The second is process research: work examining how culture conditions affect the proportion of MUSE cells within a mesenchymal population a proportion whose measurement and denominators are set out in MUSE cells vs. mesenchymal stem cells. That question sits upstream of every application area, because it determines what a given preparation contains.
It establishes nothing about clinical benefit. Every finding described above is preclinical, in animal models, with the exception of one observational study in which nothing was administered. Nothing on this page establishes that MUSE cells treat, cure, prevent or diagnose any condition.
The material CellGenic supplies is for laboratory research use only and must not be administered to humans or animals in any form. The studies surveyed here were conducted by third parties with their own materials under their own determinations, and are described as published literature. Manufacturing is cGMP, processing is performed in an ISO 7 cleanroom, and a certificate of analysis is issued for every batch, identified by batch number.
Apply for Provider Access to review batch documentation and certificates of analysis.
References
- Nose-to-brain delivery of human muse cells enhances structural and functional recovery in the murine ischemic stroke model. Scientific Reports. 2025;15(1):16243. PubMed / PMC →
- Intravenous transplantation of multi-lineage differentiating stress enduring cell promotes functional recovery after traumatic brain injury in mice. Scientific Reports. 2026;16(1):9458. Nature / PMC →
- Human Muse cells reduce myocardial infarct size and improve cardiac function without causing arrythmias in a swine model of acute myocardial infarction. PLOS ONE. 2022;17(3):e0265347. PubMed / PMC →journals.plos
- Intravenous administration of human Muse cells recovers blood flow in a mouse model of hindlimb ischemia. Frontiers in Cardiovascular Medicine. 2022;9:981088. PubMed / PMC →
- Accumulation of endogenous Muse cells in the myocardium and its pathophysiological role in patients with fulminant myocarditis. Clinical and Translational Science. 2024;17(11):e70067. PubMed / PMC →
- Muse Cells, Nontumorigenic Pluripotent-Like Stem Cells, Have Liver Regeneration Capacity Through Specific Homing and Cell Replacement in a Mouse Model of Liver Fibrosis. Cell Transplantation. 2017;26(5):821–840. PubMed →
- Protection of liver sinusoids by intravenous administration of human Muse cells in a rat extra-small partial liver transplantation model. American Journal of Transplantation. 2021;21(7):2403–2415. PubMed →
- Discontinuation of the development of a regenerative medicine product (CL2020) using Muse cells. Mitsubishi Chemical Group Corporate Announcement. 14 February 2023. Official Release →
